Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b17e402470991c7d41aff5acf79b717 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-6081 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0647 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-867 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0789 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 |
filingDate |
2012-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2020-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81008bdbd2a7adf1342815390d14c1e3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e075db5521129e130e96ce0639484679 |
publicationDate |
2020-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
ES-2769270-T3 |
titleOfInvention |
Compounds for enhanced viral transduction |
abstract |
A method of increasing the transduction efficiency of hematopoietic stem or progenitor cells cultured with a lentivirus comprising: culturing the hematopoietic stem or progenitor cells and the lentivirus in a culture medium comprising prostaglandin E2 (PGE2) or 16,16-dimethyl PGE2; wherein the hematopoietic stem or progenitor cells are cultured in the presence of PGE2 or 16,16-dimethyl PGE2 during transduction. |
priorityDate |
2011-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |